 Michael McDermott
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 5 | 2020 | 22 | 1.570 |
Why?
| | Hypothyroidism | 5 | 2020 | 68 | 1.490 |
Why?
| | Thyroid Neoplasms | 3 | 2020 | 380 | 0.730 |
Why?
| | Graves Disease | 2 | 2020 | 32 | 0.690 |
Why?
| | Osteoporosis | 5 | 2009 | 239 | 0.680 |
Why?
| | Triiodothyronine | 3 | 2020 | 55 | 0.660 |
Why?
| | Iodine Radioisotopes | 5 | 2020 | 138 | 0.610 |
Why?
| | Thyroxine | 3 | 2020 | 67 | 0.590 |
Why?
| | Bone Density Conservation Agents | 2 | 2009 | 82 | 0.520 |
Why?
| | Thyroid Diseases | 4 | 2005 | 45 | 0.510 |
Why?
| | Thyrotropin | 5 | 2020 | 120 | 0.510 |
Why?
| | Thyrotoxicosis | 2 | 2020 | 7 | 0.500 |
Why?
| | Vitamins | 2 | 2008 | 184 | 0.470 |
Why?
| | Antithyroid Agents | 4 | 2020 | 12 | 0.460 |
Why?
| | Vitamin D | 3 | 2008 | 405 | 0.460 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1415 | 0.430 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2627 | 0.380 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 46 | 0.350 |
Why?
| | Vitamin D Deficiency | 3 | 2009 | 190 | 0.330 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1518 | 0.320 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 2218 | 0.290 |
Why?
| | Self Administration | 2 | 2025 | 122 | 0.280 |
Why?
| | Premenopause | 1 | 2009 | 129 | 0.270 |
Why?
| | Patient Education as Topic | 2 | 2015 | 781 | 0.260 |
Why?
| | Thyroidectomy | 2 | 2020 | 96 | 0.240 |
Why?
| | Endocrinology | 2 | 2004 | 77 | 0.230 |
Why?
| | Thyroid Hormones | 2 | 2020 | 69 | 0.230 |
Why?
| | Pharmacists | 1 | 2008 | 259 | 0.220 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 109 | 0.210 |
Why?
| | Bone Density | 4 | 2009 | 493 | 0.210 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.210 |
Why?
| | Blood Glucose | 3 | 2023 | 2359 | 0.200 |
Why?
| | Reproductive Medicine | 1 | 2004 | 19 | 0.200 |
Why?
| | Professional Practice | 1 | 2003 | 57 | 0.200 |
Why?
| | Humans | 32 | 2025 | 147293 | 0.200 |
Why?
| | Hospitalization | 2 | 2020 | 2496 | 0.190 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2002 | 5 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2025 | 300 | 0.190 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1046 | 0.180 |
Why?
| | Whole-Body Counting | 1 | 2002 | 7 | 0.180 |
Why?
| | Thyroglobulin | 1 | 2002 | 29 | 0.180 |
Why?
| | Hip Fractures | 1 | 2003 | 88 | 0.170 |
Why?
| | Point Mutation | 1 | 2002 | 245 | 0.170 |
Why?
| | Diet | 2 | 2023 | 1284 | 0.170 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 1107 | 0.170 |
Why?
| | Thyroid Gland | 1 | 2002 | 93 | 0.170 |
Why?
| | Insulin | 2 | 2016 | 2526 | 0.160 |
Why?
| | Methimazole | 1 | 2020 | 5 | 0.160 |
Why?
| | Myxedema | 1 | 2020 | 1 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2025 | 537 | 0.160 |
Why?
| | Absorptiometry, Photon | 3 | 2009 | 277 | 0.150 |
Why?
| | Treatment Failure | 1 | 2020 | 360 | 0.150 |
Why?
| | Physical Examination | 1 | 2020 | 245 | 0.140 |
Why?
| | Reference Values | 1 | 2020 | 800 | 0.140 |
Why?
| | Triiodothyronine, Reverse | 1 | 2018 | 2 | 0.140 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 252 | 0.140 |
Why?
| | Thyroid Function Tests | 1 | 2018 | 19 | 0.140 |
Why?
| | Female | 18 | 2025 | 80076 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1598 | 0.140 |
Why?
| | Risk Factors | 5 | 2020 | 11017 | 0.140 |
Why?
| | Mass Screening | 3 | 2020 | 1375 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2006 | 1379 | 0.130 |
Why?
| | Hypoglycemia | 2 | 2016 | 489 | 0.120 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 118 | 0.120 |
Why?
| | Insulin Antibodies | 1 | 2016 | 103 | 0.110 |
Why?
| | Biomarkers | 2 | 2020 | 4351 | 0.110 |
Why?
| | Rituximab | 1 | 2016 | 211 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2020 | 606 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2020 | 886 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1166 | 0.100 |
Why?
| | Aged | 10 | 2025 | 26514 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2016 | 261 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2015 | 225 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2020 | 3660 | 0.090 |
Why?
| | Body Composition | 2 | 2023 | 694 | 0.090 |
Why?
| | Ambulatory Care | 2 | 2008 | 625 | 0.090 |
Why?
| | Thyroid Crisis | 1 | 2012 | 8 | 0.090 |
Why?
| | Age Factors | 2 | 2012 | 3372 | 0.090 |
Why?
| | Pregnancy | 3 | 2020 | 7274 | 0.090 |
Why?
| | Sex Factors | 2 | 2012 | 2136 | 0.090 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 471 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 266 | 0.090 |
Why?
| | Postpartum Thyroiditis | 1 | 2011 | 1 | 0.090 |
Why?
| | Obesity | 3 | 2023 | 3149 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 567 | 0.080 |
Why?
| | Drug Interactions | 1 | 2012 | 405 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2008 | 8430 | 0.080 |
Why?
| | Risk | 1 | 2012 | 927 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2020 | 17560 | 0.070 |
Why?
| | Adipokines | 1 | 2009 | 57 | 0.070 |
Why?
| | Liver Diseases | 1 | 2012 | 307 | 0.070 |
Why?
| | Colorado | 4 | 2009 | 4591 | 0.070 |
Why?
| | Male | 11 | 2025 | 73950 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 101 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2012 | 428 | 0.070 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 15 | 0.070 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 76 | 0.070 |
Why?
| | Patient Care | 1 | 2008 | 121 | 0.060 |
Why?
| | Diphosphonates | 1 | 2008 | 68 | 0.060 |
Why?
| | Nutrition Policy | 1 | 2007 | 57 | 0.060 |
Why?
| | Professional Role | 1 | 2008 | 171 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 90 | 0.060 |
Why?
| | Women's Health | 1 | 2009 | 317 | 0.060 |
Why?
| | Insulin Lispro | 1 | 2006 | 44 | 0.060 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 69 | 0.060 |
Why?
| | Serum Albumin | 1 | 2007 | 147 | 0.060 |
Why?
| | Pilot Projects | 2 | 2009 | 1912 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 504 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1431 | 0.060 |
Why?
| | Middle Aged | 7 | 2025 | 36821 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 516 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2009 | 697 | 0.050 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6164 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 591 | 0.050 |
Why?
| | Fractures, Bone | 1 | 2009 | 433 | 0.050 |
Why?
| | Outpatients | 1 | 2007 | 450 | 0.050 |
Why?
| | Densitometry | 1 | 2003 | 36 | 0.050 |
Why?
| | Thyroid Nodule | 1 | 2003 | 67 | 0.050 |
Why?
| | Hospitals, University | 1 | 2003 | 176 | 0.050 |
Why?
| | Ossification, Heterotopic | 1 | 2002 | 18 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 73 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2023 | 135 | 0.040 |
Why?
| | Medical Records | 1 | 2003 | 192 | 0.040 |
Why?
| | Inpatients | 1 | 2006 | 556 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2002 | 116 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 928 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2002 | 186 | 0.040 |
Why?
| | Exons | 1 | 2002 | 365 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 948 | 0.040 |
Why?
| | Calcium | 1 | 2007 | 1197 | 0.040 |
Why?
| | Calcinosis | 1 | 2002 | 234 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 219 | 0.040 |
Why?
| | Prevalence | 1 | 2007 | 2889 | 0.040 |
Why?
| | Adult | 5 | 2025 | 41405 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2175 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 6011 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2134 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5476 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1371 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2886 | 0.030 |
Why?
| | Weight Loss | 1 | 2023 | 867 | 0.030 |
Why?
| | Exercise | 1 | 2009 | 2219 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3784 | 0.030 |
Why?
| | Patient Discharge | 1 | 2003 | 1002 | 0.030 |
Why?
| | Lung Diseases | 1 | 2002 | 787 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2002 | 1339 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 8164 | 0.030 |
Why?
| | Algorithms | 1 | 2002 | 1868 | 0.020 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 703 | 0.020 |
Why?
| | Resistin | 1 | 2009 | 12 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 39 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2973 | 0.020 |
Why?
| | Medical Audit | 1 | 2008 | 77 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 173 | 0.020 |
Why?
| | Leptin | 1 | 2009 | 249 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 244 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 259 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2015 | 1253 | 0.010 |
Why?
| | Body Mass Index | 1 | 2015 | 2470 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1224 | 0.010 |
Why?
| | Program Evaluation | 1 | 2008 | 952 | 0.010 |
Why?
| | Review Literature as Topic | 1 | 2002 | 53 | 0.010 |
Why?
| | Animals | 1 | 2023 | 38410 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 11947 | 0.010 |
Why?
| | Lung | 1 | 2009 | 4141 | 0.010 |
Why?
|
|
McDermott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|